Drug intelligence / Profile preview

Asarel

Development stage: Unknown
Lead developer: Megat Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Asarel** is an Ecuadorian prescription fixed-dose oral antiemetic product marketed by Megat. Each enteric tablet contains doxylamine 10 mg plus pyridoxine 10 mg and is indicated for nausea and vomiting of pregnancy, including management of hyperemesis gravidarum. Doxylamine is a first-generation histamine H1-receptor antagonist with central antiemetic activity, while pyridoxine is vitamin B6 and contributes to the combination's anti-nausea therapeutic effect. ([megat.com.ec](https://megat.com.ec/productos/))

Brand names: Asarel
Other names: doxilamina + piridoxinadoxylamine + pyridoxinedoxylamine succinate + pyridoxine hydrochloride

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Asarel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asarel.

Explore the full profile